Verastem Stock Forecast, Price & News

-0.05 (-1.51 %)
(As of 07/30/2021 12:58 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume6,641 shs
Average Volume2.78 million shs
Market Capitalization$562.18 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

Verastem logo

About Verastem

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.


Verastem (NASDAQ:VSTM) Shares Gap Down to $3.57
Verastem (NASDAQ:VSTM) Shares Gap Down to $3.57
July 22, 2021 |
Verastem (NASDAQ:VSTM)  Shares Down 3.8%
Verastem (NASDAQ:VSTM) Shares Down 3.8%
July 21, 2021 |
Verastem (NASDAQ:VSTM) PT Raised to $5.00
Verastem (NASDAQ:VSTM) PT Raised to $5.00
July 20, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.71 out of 5 stars

Medical Sector

669th out of 2,216 stocks

Pharmaceutical Preparations Industry

343rd out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Verastem (NASDAQ:VSTM) Frequently Asked Questions

Is Verastem a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Verastem stock.
View analyst ratings for Verastem
or view top-rated stocks.

What stocks does MarketBeat like better than Verastem?

Wall Street analysts have given Verastem a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Verastem wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Verastem?

Verastem saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 13,380,000 shares, an increase of 27.6% from the June 15th total of 10,490,000 shares. Based on an average trading volume of 2,860,000 shares, the short-interest ratio is presently 4.7 days. Currently, 7.9% of the shares of the company are short sold.
View Verastem's Short Interest

When is Verastem's next earnings date?

Verastem is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Verastem

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) issued its quarterly earnings results on Tuesday, May, 11th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). The biopharmaceutical company had revenue of $1.01 million for the quarter. Verastem had a negative net margin of 53.00% and a negative trailing twelve-month return on equity of 38.76%.
View Verastem's earnings history

How has Verastem's stock been impacted by COVID-19 (Coronavirus)?

Verastem's stock was trading at $2.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VSTM shares have increased by 34.0% and is now trading at $3.27.
View which stocks have been most impacted by COVID-19

What price target have analysts set for VSTM?

4 equities research analysts have issued twelve-month target prices for Verastem's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate Verastem's share price to reach $6.33 in the next year. This suggests a possible upside of 93.7% from the stock's current price.
View analysts' price targets for Verastem
or view top-rated stocks among Wall Street analysts.

Who are Verastem's key executives?

Verastem's management team includes the following people:
  • Mr. Brian M. Stuglik BPHARM, R.Ph., RPh, CEO & Director (Age 62, Pay $1.16M)
  • Mr. Daniel W. Paterson, COO & Pres (Age 60, Pay $780.11k)
  • Mr. Robert E. Gagnon, Chief Bus. & Financial Officer (Age 47, Pay $651.22k)
  • Mr. Richard H. Aldrich M.B.A., Mba, Founder and Consultant (Age 67)
  • Dr. Robert A. Weinberg, nder & Former Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta Ph.D., Co-Founder
  • Dr. Michelle Dipp, Co-Founder (Age 45)
  • Dr. Jonathan Pachter Ph.D., Chief Scientific Officer (Age 63)
  • Ms. Erin S. Cox, Sr. Director of Investor Relations & Corp. Communications
  • Mr. Sean C. Flynn, VP, Gen. Counsel & Sec. (Age 47)

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem CEO Robert Forrester on Robert Forrester has an approval rating of 100% among Verastem's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Verastem's key competitors?

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $3.27.

How much money does Verastem make?

Verastem has a market capitalization of $562.18 million and generates $88.52 million in revenue each year. The biopharmaceutical company earns $-67,730,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

How many employees does Verastem have?

Verastem employs 48 workers across the globe.

What is Verastem's official website?

The official website for Verastem is

Where are Verastem's headquarters?

Verastem is headquartered at 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.